Claims for Patent: 10,675,286

Summary for Patent: 10,675,286

Title:	Heterocyclic compounds and uses thereof
Abstract:	Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
Inventor(s):	Kutok; Jeffery L. (Natick, MA), Winkler; David G. (Arlington, MA), Palombella; Vito J. (Needham, MA)
Assignee:	Infinity Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:	15/672,964
Patent Claims:	1. A method of treating a solid tumor in a subject, comprising administering to the subject a therapeutically effective amount of a compound of the formula: ##STR01609## or a pharmaceutically acceptable salt thereof, in combination with an anti-PD-1 antibody, wherein the solid tumor is melanoma, gall bladder cancer, triple negative breast cancer, adrenal gland cancer, or mesothelioma. 2. The method of claim 1, wherein the anti-PD-1 antibody is pembrolizumab. 3. The method of claim 1, wherein the anti-PD-1 antibody is nivolumab. 4. The method of claim 1, wherein the solid tumor is melanoma. 5. The method of claim 4, wherein the melanoma is relapsed after or refractory to a prior therapy, and wherein the prior therapy is an immune checkpoint therapy. 6. The method of claim 1, wherein the solid tumor is gall bladder cancer. 7. The method of claim 1, wherein the solid tumor is triple negative breast cancer. 8. The method of claim 7, wherein the triple negative breast cancer is naive to immune checkpoint therapy. 9. The method of claim 8, wherein the immune checkpoint therapy is a treatment by a PD-1 or PD-L1 inhibitor. 10. The method of claim 1, wherein the solid tumor is adrenal gland cancer. 11. The method of claim 1, wherein the solid tumor is mesothelioma. 12. The method of claim 11, wherein the mesothelioma is epithelioid mesothelioma, sarcomatoid mesothelioma, or biphasic mesothelioma. 13. The method of claim 1, wherein the compound is administered at a dose of about 1-60 mg once daily. 14. The method of claim 1, wherein the compound is administered at a dose of about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, or about 60 mg once daily. 15. The method of claim 14, wherein the compound is administered at a dose of about 30 mg once daily. 16. The method of claim 14, wherein the compound is administered at a dose of about 40 mg once daily. 17. The method of claim 1, wherein the anti-PD-1 antibody is administered at a dose of 1 to 5 mg/kg every 2 weeks. 18. The method of claim 17, wherein the anti-PD-1 antibody is administered at a dose of about 3 mg/kg every 2 weeks. 19. The method of claim 1, wherein the subject has a high number of MDSC, compared to a reference value.

Details for Patent 10,675,286

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	KEYTRUDA	pembrolizumab	For Injection	125514	09/04/2014		2034-03-19
Merck Sharp & Dohme Corp.	KEYTRUDA	pembrolizumab	Injection	125514	01/15/2015		2034-03-19
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554	12/22/2014		2034-03-19
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554	10/04/2017		2034-03-19
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554	08/27/2021		2034-03-19